Clinical Trial Update: CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CD7 CAR T-cell therapy in refractory/relapsed CD7+ T cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• CD7 CAR-T cell (CD7-targeted CAR-T cell)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Refractory and Relapsed T Cell Lymphoma | Phase 2 | Status: UNKNOWN